Anaptysbio Shares Outstanding History (ANAB)
Anaptysbio reported 28.0M shares outstanding at the end of fiscal 2025.
View full Anaptysbio company overviewAnaptysbio annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 28.0M | −2.5M | −8.05% |
| 2024 | 2024-12-31 | 30.5M | 3.9M | +14.57% |
| 2023 | 2023-12-31 | 26.6M | −1.9M | −6.72% |
| 2022 | 2022-12-31 | 28.5M | 866,000 | +3.13% |
| 2021 | 2021-12-31 | 27.6M | 291,000 | +1.06% |
| 2020 | 2020-12-31 | 27.4M | 101,000 | +0.37% |
| 2019 | 2019-12-31 | 27.3M | 333,000 | +1.24% |
| 2018 | 2018-12-31 | 26.9M | 3.1M | +13.16% |
| 2017 | 2017-12-31 | 23.8M | 21.1M | +797.43% |
| 2016 | 2016-12-31 | 2.7M | — | — |
Anaptysbio quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 29.0M | −1.4M | −4.47% |
| Q4 2025 | 2025-12-31 | 28.0M | −2.5M | −8.05% |
| Q3 2025 | 2025-09-30 | 27.6M | −2.9M | −9.38% |
| Q2 2025 | 2025-06-30 | 28.0M | 538,964 | +1.96% |
| Q1 2025 | 2025-03-31 | 30.4M | 3.1M | +11.24% |
| Q4 2024 | 2024-12-31 | 30.5M | 3.9M | +14.57% |
| Q3 2024 | 2024-09-30 | 30.4M | 3.9M | +14.50% |
| Q2 2024 | 2024-06-30 | 27.4M | 903,338 | +3.40% |
| Q1 2024 | 2024-03-31 | 27.3M | 298,447 | +1.10% |
| Q4 2023 | 2023-12-31 | 26.6M | −1.9M | −6.72% |
| Q3 2023 | 2023-09-30 | 26.6M | −1.8M | −6.27% |
| Q2 2023 | 2023-06-30 | 26.5M | −1.7M | −6.02% |
| Q1 2023 | 2023-03-31 | 27.0M | −1.2M | −4.11% |
| Q4 2022 | 2022-12-31 | 28.5M | 866,000 | +3.13% |
| Q3 2022 | 2022-09-30 | 28.4M | 900,384 | +3.28% |
| Q2 2022 | 2022-06-30 | 28.2M | 798,735 | +2.91% |
| Q1 2022 | 2022-03-31 | 28.2M | 810,235 | +2.96% |
| Q4 2021 | 2021-12-31 | 27.6M | 291,000 | +1.06% |
| Q3 2021 | 2021-09-30 | 27.5M | 107,555 | +0.39% |
| Q2 2021 | 2021-06-30 | 27.4M | 145,271 | +0.53% |
| Q1 2021 | 2021-03-31 | 27.4M | 90,240 | +0.33% |
| Q4 2020 | 2020-12-31 | 27.4M | 101,000 | +0.37% |
| Q3 2020 | 2020-09-30 | 27.3M | 248,186 | +0.92% |
| Q2 2020 | 2020-06-30 | 27.3M | 242,811 | +0.90% |
| Q1 2020 | 2020-03-31 | 27.3M | 270,822 | +1.00% |
| Q4 2019 | 2019-12-31 | 27.3M | 333,000 | +1.24% |
| Q3 2019 | 2019-09-30 | 27.1M | 349,329 | +1.31% |
| Q2 2019 | 2019-06-30 | 27.0M | 3.0M | +12.55% |
| Q1 2019 | 2019-03-31 | 27.0M | 3.2M | +13.39% |
| Q4 2018 | 2018-12-31 | 26.9M | 3.1M | +13.16% |
| Q3 2018 | 2018-09-30 | 26.7M | 6.3M | +30.51% |
| Q2 2018 | 2018-06-30 | 24.0M | 3.7M | +18.43% |
| Q1 2018 | 2018-03-31 | 23.8M | 3.6M | +17.62% |
| Q4 2017 | 2017-12-31 | 23.8M | 21.1M | +797.43% |
| Q3 2017 | 2017-09-30 | 20.5M | — | — |
| Q2 2017 | 2017-06-30 | 20.3M | — | — |
| Q1 2017 | 2017-03-31 | 20.2M | — | — |
| Q4 2016 | 2016-12-31 | 2.7M | — | — |
Anaptysbio shares outstanding trends
Over the last five reported fiscal years, Anaptysbio's shares outstanding moved from 27.4M to 28.0M, a change of 662,845. The latest reported quarter, Q1 2026, shows 29.0M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anaptysbio filings at SEC.gov ↗